Facebook
Britain's News Portal
Around The Clock
BREAKING
Loading latest headlines…

New pill shows promise for advanced pancreatic cancer patients

A new drug, daraxonrasib, has been hailed as a significant breakthrough for advanced pancreatic cancer, with trials showing tumours stopped growing in almost all patients.

  • In a trial of 61 patients with advanced pancreatic cancer, tumours stopped growing in almost all participants.
  • For one in 12 patients, the cancer became undetectable after treatment with daraxonrasib.
  • A year after starting treatment, 76.6% of patients were alive, compared to 40-45% for chemotherapy alone.

A new pill, daraxonrasib, is being described as the biggest treatment breakthrough for pancreatic cancer in decades. During a trial, the drug caused tumours to stop growing in almost all of the 61 patients with advanced pancreatic cancer that had spread to other parts of the body.

For one in 12 patients in the trial, the cancer became undetectable. Tumours shrank or disappeared in just over 60% of patients, and for about 8% of patients, tumours became undetectable on CT scans.

Doctors caution that the pill is not yet considered a cure, and the duration of its effectiveness is unknown. However, it is hoped it will offer patients more time. A year after starting treatment, 76.6% of patients were alive, compared to the 40-45% typically seen with chemotherapy alone.

Daraxonrasib is a KRAS inhibitor treatment that targets and deactivates specific mutations found in most pancreatic cancers, which drive tumour growth. Michelle Mitchell, Cancer Research UK's chief executive, stated that more research is needed but called it "the biggest leap forward we've seen in decades for pancreatic cancer patients."

Why this matters: Pancreatic cancer has the lowest survival rate of all common cancers in the UK, with only about 3% of patients surviving five years when the disease has spread.

Related Articles

Get the news that matters.

Join thousands of readers getting the best of British news straight to their inbox.